Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience.

Desterro J, McLornan DP, Curto Garcia N, O'Sullivan J, Alimam S, Keohane C, Woodley C, Francis Y, Kordasti S, Radia DH, Harrison CN.

Br J Haematol. 2019 May 15. doi: 10.1111/bjh.15968. [Epub ahead of print]

PMID:
31090926
2.

Diagnosis and management of primary immune thrombocytopenia in adults.

Ejaz A, Radia D.

Br J Hosp Med (Lond). 2019 Apr 2;80(4):C54-C57. doi: 10.12968/hmed.2019.80.4.C54. No abstract available.

PMID:
30951423
3.

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age, a systematic review.

Ianotto JC, Curto-Garcia N, Lauermannova M, Radia D, Kiladjian JJ, Harrison CN.

Haematologica. 2019 Jan 24. pii: haematol.2018.200832. doi: 10.3324/haematol.2018.200832. [Epub ahead of print]

4.

Mast cell activation syndrome: Importance of consensus criteria and call for research.

Valent P, Akin C, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, Reiter A, Gotlib J, Castells M, Milner JD, Carter MC, Komarow H, Radia D, Pardanani A, Sotlar K, Triggiani M, Horny HP, Arock M, Schwartz LB, Metcalfe DD.

J Allergy Clin Immunol. 2018 Sep;142(3):1008-1010. doi: 10.1016/j.jaci.2018.06.004. Epub 2018 Jun 19. No abstract available.

PMID:
29928922
5.

Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations.

Alimam S, McLornan DP, Jiang J, Radia D, Mufti GJ, Harrison CN.

Haematologica. 2018 Jun;103(6):e234-e236. doi: 10.3324/haematol.2017.180851. Epub 2017 Nov 30. No abstract available.

6.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
7.

Evidence for more cost-effective surveillance options for bovine spongiform encephalopathy (BSE) and scrapie in Great Britain.

Wall BA, Arnold ME, Radia D, Gilbert W, Ortiz-Pelaez A, Stärk KD, Van Klink E, Guitian J.

Euro Surveill. 2017 Aug 10;22(32). pii: 30594. doi: 10.2807/1560-7917.ES.2017.22.32.30594.

8.

Guideline for the investigation and management of eosinophilia.

Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, Ewing J, Harrison CN, Knapper S, McLornan D, Mead AJ, Radia D, Bain BJ; British Committee for Standards in Haematology.

Br J Haematol. 2017 Feb;176(4):553-572. doi: 10.1111/bjh.14488. Epub 2017 Jan 23. No abstract available.

9.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

10.

Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.

Beauverd Y, Alimam S, McLornan DP, Radia DH, Harrison CN.

Br J Haematol. 2016 Oct;175(1):37-42. doi: 10.1111/bjh.14173. Epub 2016 Jun 13.

PMID:
27293069
11.

Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms.

Curto-García N, Harrison CN, McLornan DP, Radia DH.

Br J Haematol. 2017 Jul;178(2):338-340. doi: 10.1111/bjh.14128. Epub 2016 May 2. No abstract available.

PMID:
27135305
12.

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.

Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA.

Cancer. 2016 Jun 15;122(12):1888-96. doi: 10.1002/cncr.30013. Epub 2016 Apr 12.

13.

Beneficial effects of JAK inhibitor therapy in Systemic Mastocytosis.

Dowse R, Ibrahim M, McLornan DP, Moonim MT, Harrison CN, Radia DH.

Br J Haematol. 2017 Jan;176(2):324-327. doi: 10.1111/bjh.13951. Epub 2016 Feb 5. No abstract available.

PMID:
26847591
14.

Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

Beauverd Y, McLornan DP, Radia DH, Harrison CN.

Future Oncol. 2016 Mar;12(6):739-49. doi: 10.2217/fon-2015-0023. Epub 2016 Feb 5. Review.

PMID:
26846873
15.

Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.

Beauverd Y, Radia D, Cargo C, Knapper S, Drummond M, Pillai A, Harrison C, Robinson S.

Haematologica. 2016 May;101(5):e182-4. doi: 10.3324/haematol.2015.139691. Epub 2016 Jan 27. No abstract available.

16.

Management of symptoms in polycythemia vera and essential thrombocythemia patients.

Radia D, Geyer HL.

Hematology Am Soc Hematol Educ Program. 2015;2015:340-8. doi: 10.1182/asheducation-2015.1.340. Review.

PMID:
26637741
17.

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA.

J Clin Oncol. 2016 Jan 10;34(2):151-9. doi: 10.1200/JCO.2015.62.9337. Epub 2015 Nov 23.

18.

Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.

Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, Matito A, Broesby-Olsen S, Siebenhaar F, Lange M, Niedoszytko M, Castells M, Oude Elberink JNG, Bonadonna P, Zanotti R, Hornick JL, Torrelo A, Grabbe J, Rabenhorst A, Nedoszytko B, Butterfield JH, Gotlib J, Reiter A, Radia D, Hermine O, Sotlar K, George TI, Kristensen TK, Kluin-Nelemans HC, Yavuz S, Hägglund H, Sperr WR, Schwartz LB, Triggiani M, Maurer M, Nilsson G, Horny HP, Arock M, Orfao A, Metcalfe DD, Akin C, Valent P.

J Allergy Clin Immunol. 2016 Jan;137(1):35-45. doi: 10.1016/j.jaci.2015.08.034. Epub 2015 Oct 21. Review.

PMID:
26476479
19.

Immune reconstitution inflammatory syndrome in a patient with HIV presenting as severe mixed haemolytic anaemia.

Mwirigi A, Stockwell S, Radia D, Kulasegaram R, Kesse-Adu R.

Int J STD AIDS. 2016 Oct;27(11):1019-22. doi: 10.1177/0956462415611521. Epub 2015 Oct 13.

PMID:
26468273
20.

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.

Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P.

Leukemia. 2016 Feb;30(2):464-72. doi: 10.1038/leu.2015.242. Epub 2015 Sep 9.

21.

How We Treat Myeloproliferative Neoplasms.

Harrison CN, McLornan DP, Francis YA, Woodley C, Provis L, Radia DH.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S19-26. doi: 10.1016/j.clml.2015.02.032.

PMID:
26297273
22.

The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.

Keohane C, McLornan DP, Sanchez K, Connor C, Radia D, Harrison CN.

Haematologica. 2015 Sep;100(9):e348-50. doi: 10.3324/haematol.2015.128918. Epub 2015 Jun 18. No abstract available.

23.

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.

Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Müllauer L, Schwaab J, Hoffmann T, Bradner JE, Radia D, Sperr WR, Hoermann G, Reiter A, Horny HP, Zuber J, Arock M, Valent P.

Leukemia. 2015 Nov;29(11):2230-7. doi: 10.1038/leu.2015.138. Epub 2015 Jun 9.

24.

Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.

Mwirigi A, Galli S, Keohane C, Raj K, Radia DH, Harrison CN, McLornan DP.

Br J Haematol. 2014 Dec;167(5):714-6. doi: 10.1111/bjh.13046. Epub 2014 Jul 22. No abstract available.

PMID:
25048366
25.

Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.

Harrison CN, Butt N, Campbell P, Conneally E, Drummond M, Green AR, Murrin R, Radia DH, Mead A, Reilly JT, Cross NC, McMullin MF.

Br J Haematol. 2014 Nov;167(3):421-3. doi: 10.1111/bjh.12986. Epub 2014 Jun 17. No abstract available.

PMID:
24935860
26.

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis.

Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink JN, Kristensen T, Butterfield JH, Triggiani M, Alvarez-Twose I, Reiter A, Sperr WR, Sotlar K, Yavuz S, Kluin-Nelemans HC, Hermine O, Radia D, van Doormaal JJ, Gotlib J, Orfao A, Siebenhaar F, Schwartz LB, Castells M, Maurer M, Horny HP, Akin C, Metcalfe DD, Arock M; European Competence Network on Mastocytosis.

Allergy. 2014 Oct;69(10):1267-74. doi: 10.1111/all.12436. Epub 2014 May 19.

PMID:
24836395
27.

Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.

Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, George TI, Kluin-Nelemans HC, Hermine O, Butterfield JH, Hägglund H, Ustun C, Hornick JL, Triggiani M, Radia D, Akin C, Hartmann K, Gotlib J, Schwartz LB, Verstovsek S, Orfao A, Metcalfe DD, Arock M, Horny HP.

Ann Oncol. 2014 Sep;25(9):1691-700. doi: 10.1093/annonc/mdu047. Epub 2014 Mar 27. Review.

28.

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.

Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA.

Blood. 2014 Jun 12;123(24):3803-10. doi: 10.1182/blood-2013-09-527903. Epub 2014 Feb 19.

29.

Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.

Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN.

Haematologica. 2013 Dec;98(12):1872-6. doi: 10.3324/haematol.2013.095109. Epub 2013 Sep 20.

30.

Treatment and management of myelofibrosis in the era of JAK inhibitors.

Keohane C, Radia DH, Harrison CN.

Biologics. 2013;7:189-98. doi: 10.2147/BTT.S34942. Epub 2013 Aug 20. Erratum in: Biologics. 2013;7:231.

31.

Anemia management: development of a rapidaccess anemia and intravenous iron service.

Radia D, Momoh I, Dillon R, Francis Y, Cameron L, Fagg TL, Overland H, Robinson S, Harrison CN.

Risk Manag Healthc Policy. 2013 Aug 6;6:13-22. doi: 10.2147/RMHP.S41818. eCollection 2013.

32.

Relationship between periparturient management, prevalence of MAP and preventable economic losses in UK dairy herds.

Radia D, Bond K, Limon G, van Winden S, Guitian J.

Vet Rec. 2013 Oct 12;173(14):343. doi: 10.1136/vr.101408. Epub 2013 Jul 29. Review.

PMID:
23897995
33.

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.

Gleixner KV, Peter B, Blatt K, Suppan V, Reiter A, Radia D, Hadzijusufovic E, Valent P.

Haematologica. 2013 Sep;98(9):1450-7. doi: 10.3324/haematol.2012.079202. Epub 2013 Mar 28.

34.

Diagnostic pathway for the investigation of thrombocytosis.

Harrison CN, Butt N, Campbell P, Conneally E, Drummond M, Green AR, Murrin R, Radia DH, Reilly JT, McMullin MF.

Br J Haematol. 2013 May;161(4):604-6. doi: 10.1111/bjh.12283. Epub 2013 Mar 11. No abstract available.

PMID:
23480550
35.

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.

Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L, Gleixner KV, Grattan C, Hadzijusufovic E, Hägglund H, Hermine O, Horny HP, Kluin-Nelemans HC, Maurer M, Niedoszytko M, Nedoszytko B, Nilsson G, Oude-Elberink HN, Orfao A, Radia D, Reiter A, Siebenhaar F, Sotlar K, Sperr WR, Triggiani M, VanDoormaal JJ, Várkonyi J, Yavuz S, Hartmann K.

Wien Klin Wochenschr. 2012 Dec;124(23-24):807-14. doi: 10.1007/s00508-012-0293-z. Epub 2012 Nov 20. Review.

PMID:
23179435
36.

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts.

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B.

Br J Haematol. 2013 Jan;160(2):228-36. doi: 10.1111/bjh.12118. Epub 2012 Nov 15.

PMID:
23151086
37.

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA.

J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590. Ferarri, Maria L [corrected to Ferrari, Maria L].

38.

Erythropoietin provides a useful strategy for treating preoperative anemia in planned elective orthopedic surgery: an analysis of benefit in routine practice.

Qureshi M, Momoh I, Bankes M, Earnshaw P, Radia D, Harrison C.

Transfusion. 2012 Sep;52(9):2063-4. doi: 10.1111/j.1537-2995.2012.03722.x. No abstract available.

PMID:
22946973
39.

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.

Gowin K, Thapaliya P, Samuelson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell C, Mesa R.

Haematologica. 2012 Oct;97(10):1570-3. doi: 10.3324/haematol.2011.061390. Epub 2012 Mar 14.

40.

Comparative efficacy of three forms of parenteral iron.

Dillon R, Momoh I, Francis Y, Cameron L, Harrison CN, Radia D.

J Blood Transfus. 2012;2012:473514. doi: 10.1155/2012/473514. Epub 2011 Nov 22.

41.

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA.

Blood. 2011 Jul 14;118(2):401-8. doi: 10.1182/blood-2011-01-328955. Epub 2011 May 2.

42.

Guideline for investigation and management of adults and children presenting with a thrombocytosis.

Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, Erber W, Everington T, Green AR, Hall GW, Hunt BJ, Ludlam CA, Murrin R, Nelson-Piercy C, Radia DH, Reilly JT, Van der Walt J, Wilkins B, McMullin MF; British Committee for Standards in Haematology.

Br J Haematol. 2010 May;149(3):352-75. doi: 10.1111/j.1365-2141.2010.08122.x. Epub 2010 Mar 15. Review. No abstract available.

PMID:
20331456
43.

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.

Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A.

Leuk Res. 2009 Sep;33(9):1199-203. doi: 10.1016/j.leukres.2009.01.035. Epub 2009 Feb 27.

44.

Low-dose thalidomide in myelofibrosis.

Weinkove R, Reilly JT, McMullin MF, Curtin NJ, Radia D, Harrison CN.

Haematologica. 2008 Jul;93(7):1100-1. doi: 10.3324/haematol.12416. Epub 2008 May 27. No abstract available.

45.

The management and outcome of four pregnancies in women with idiopathic myelofibrosis.

Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN.

Br J Haematol. 2008 Jul;142(3):480-2. doi: 10.1111/j.1365-2141.2008.07194.x. Epub 2008 May 15. Review. No abstract available.

PMID:
18492097
46.

British Society for Haematology, Slide session, Annual Scientific Meeting, Bournemouth, 2007.

Bhavnani M, Braithwaite J, Burthem J, Crotty G, Gibson B, Hutchinson C, Jackson GH, Layton M, Lucas G, Macartney C, Matthey F, Pardoe L, Radia D, Webb S.

Int J Lab Hematol. 2008 Apr;30(2):95-104. doi: 10.1111/j.1751-553X.2008.01027.x. Epub 2008 Feb 16.

PMID:
18284418
47.

Improvement of fibrosis in a patient with chronic myeloproliferative disease.

Retter A, Radia DH, Harrison CN.

Br J Haematol. 2007 Nov;139(3):350. No abstract available.

PMID:
17910624
48.

The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.

Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C.

Br J Haematol. 2006 Jan;132(2):244-5. No abstract available.

PMID:
16398659
49.

The management and outcome of 18 pregnancies in women with polycythemia vera.

Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN.

Haematologica. 2005 Nov;90(11):1477-83. Review.

50.

Supplemental Content

Support Center